The global transcriptomics technologies market is witnessing significant growth, driven by increasing investments in life sciences research, personalized medicine, and advanced drug discovery. Transcriptomics—the study of the complete set of RNA transcripts produced by cells—has become an important tool for understanding gene expression and identifying disease-specific biomarkers. As pharmaceutical and biotechnology companies increasingly focus on targeted and personalized therapeutics, demand for transcriptomics technologies continues to rise.

Growing Demand for Personalized Medicine

One of the major factors supporting the expansion of the transcriptomics technologies market is the growing emphasis on personalized healthcare. Pharmaceutical companies are investing heavily in the identification of biomarkers that can help predict disease progression and treatment responses. Transcriptomic analysis enables researchers to examine gene expression patterns and gain valuable insights into disease mechanisms, supporting the development of more effective and targeted therapies.

In addition, rising research and development expenditure and improvements in healthcare infrastructure are creating favorable conditions for market growth. Academic institutions, pharmaceutical companies, and research organizations are increasingly adopting advanced transcriptomics platforms to accelerate scientific discoveries.

The development of bioinformatics tools and services is also expected to create lucrative opportunities. The growing volume and complexity of biological research data have increased the need for sophisticated software capable of processing, storing, and interpreting large datasets. This creates opportunities for both life science companies and software developers to introduce innovative bioinformatics solutions.

The market opportunity was valued at approximately US$2.55 billion in 2015 and was projected to expand at a 15.9% CAGR between 2013 and 2019, reaching around US$4.62 billion by 2019.

PCR and Next-Generation Sequencing Drive Technology Adoption

By technology, polymerase chain reaction (PCR) remained a leading contributor to market revenue through 2019. PCR's high process efficiency, precision, amplification capabilities, and broad range of applications have supported its widespread adoption. Continuous product innovation and improvements in PCR-based technologies have further strengthened its position.

Meanwhile, next-generation sequencing (NGS) emerged as one of the fastest-growing technology segments. The segment was projected to expand at a CAGR of more than 19% during the forecast period. Rapid technological advancements, the ability to analyze cellular transcriptomes from multiple dimensions, expanding applications, and increasing outsourcing of sequencing services are among the key factors supporting NGS adoption.

Drug Discovery Remains a Key Application

Among applications, drug discovery and research represented the dominant segment in 2015 and was expected to maintain its leadership through 2019. Increasing research activities in genomics and proteomics are encouraging pharmaceutical and biotechnology companies to incorporate transcriptomics into drug development programs.

The drug discovery and research segment was projected to grow at a significant 18.2% CAGR during the forecast period, reflecting the increasing importance of gene-expression analysis in identifying therapeutic targets and understanding disease biology.

North America Leads the Global Market

North America was expected to remain the leading regional market through 2019, supported by extensive research and development activities, advanced technological infrastructure, and the presence of numerous biotechnology companies. Increasing private-sector investments in transcriptomics research are helping organizations develop targeted therapeutics, while universities and research institutes continue to conduct extensive transcriptome studies.

The region was projected to account for approximately 39% of global market revenue by 2019.

Meanwhile, Asia Pacific was expected to record an impressive CAGR of 18.0%. Growing life sciences research, expanding healthcare capabilities, and increasing outsourcing of clinical and medical research in countries such as India and China are contributing to regional growth.

Competitive Landscape

The transcriptomics technologies market features several prominent companies, including Affymetrix Inc., Agilent Technologies, F. Hoffmann-La Roche Ltd., Illumina Inc., Life Technologies Corporation, and Thermo Fisher Scientific. Continued technological innovation, strategic investments, and the development of advanced sequencing and analysis solutions are expected to shape competition in the market.

Overall, increasing demand for personalized medicine, expanding genomics research, technological advancements, and the growing importance of bioinformatics are expected to create promising opportunities for the transcriptomics technologies market.

Media Contact:

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453